NEW YORK, March 8 – Celera has signed an agreement with Lynx Therapeutics in which Lynx will provide gene expression data for integration into Celera’s database, the companies said Thursday.
Under the agreement, Celera will integrate into its databases gene expression data that Lynx, of Hayward, Calif., has already generated by analyzing health human tissue samples using its Massively Parallel Signature Sequencing technology. Lynx will also use this system to generate additional data for Celera by analyzing tissue samples that Celera selects.
Lynx's MPSS technology simultaneously generates sequence information from millions of DNA fragments using Lynx’s MegaClone proprietary cloning procedure. MegaClone turns a sample of millions of DNA molecules into one made up of millions of micro-beads, each of which carries about 100,000 copies of one of the DNA molecules in the sample.
The MPSS system identifies each molecule by a 16 to 20 base signature sequence, and can detect the levels of gene expression in cells, even when a gene is rare, Lynx said.
"This agreement between Celera and Lynx is an example of the ways that Celera is looking to enhance the utility of our genomics and related biological data sets," said Peter Barrett, Celera's chief business officer, in a statement. "With Lynx we believe we can supplement our internal discovery capabilities, as well as those of our customers, with the addition of the MPSS technology."
Celera plans to develop bioinformatics tools that allow Celera Discovery System customers to analyze Lynx’s data.
The companies did not disclose the financial terms of the agreement.